Studies have demonstrated an essential role of AMP-activated protein kinase (AMPK) dysregulation in obesity- and diabetes-associated kidney disease both in experimental and clinical models [28,29,30,31,32,33]. Here, PRKAB1 is linked to kidney disorder.